摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

吗啉-2-甲酸甲酯盐酸盐 | 937063-34-8

中文名称
吗啉-2-甲酸甲酯盐酸盐
中文别名
吗啉-2-羧酸甲酯盐酸盐;2-吗啉甲酸甲酯盐酸盐
英文名称
methyl morpholine-2-carboxylate hydrochloride
英文别名
methyl morpholine-2-carboxylate;hydrochloride
吗啉-2-甲酸甲酯盐酸盐化学式
CAS
937063-34-8
化学式
C6H11NO3*ClH
mdl
MFCD17167182
分子量
181.619
InChiKey
DYMNXWIUMADROW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.58
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.833
  • 拓扑面积:
    47.6
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:6d7cd7f7d42a697b39e5347bf00e7b98
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl morpholine-2-carboxylate, HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl morpholine-2-carboxylate, HCl
CAS number: 937063-34-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H11NO3.ClH
Molecular weight: 181.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propionic acid吗啉-2-甲酸甲酯盐酸盐1-羟基苯并三唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 二氯甲烷 为溶剂, 以100%的产率得到methyl 4-{3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl}-2-morpholinecarboxylate
    参考文献:
    名称:
    发现新型三环化合物作为角鲨烯合酶抑制剂
    摘要:
    在本文中,我们已经报道了作为鲨烯合成酶抑制剂(化合物1)的高效苯甲醛衍生物的设计,合成和鉴定。不幸的是,这些化合物的体内功效不足以获取临床候选药物。我们继续我们的研究,以得到比苯甲醛模板更有效的体内模板。 在我们的努力中,我们着眼于苯并a氮平环,并通过在其中掺入杂环来设计了一种新的三环支架。制备的吡咯并苯并x庚因衍生物显示出进一步有效的体外和体内活性。
    DOI:
    10.1016/j.bmc.2012.02.054
  • 作为产物:
    描述:
    参考文献:
    名称:
    发现新型三环化合物作为角鲨烯合酶抑制剂
    摘要:
    在本文中,我们已经报道了作为鲨烯合成酶抑制剂(化合物1)的高效苯甲醛衍生物的设计,合成和鉴定。不幸的是,这些化合物的体内功效不足以获取临床候选药物。我们继续我们的研究,以得到比苯甲醛模板更有效的体内模板。 在我们的努力中,我们着眼于苯并a氮平环,并通过在其中掺入杂环来设计了一种新的三环支架。制备的吡咯并苯并x庚因衍生物显示出进一步有效的体外和体内活性。
    DOI:
    10.1016/j.bmc.2012.02.054
点击查看最新优质反应信息

文献信息

  • [EN] HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] DÉRIVÉS HÉTÉROAROMATIQUES ET LEURS APPLICATIONS PHARMACEUTIQUES
    申请人:SUNSHINE LAKE PHARMA CO LTD
    公开号:WO2016034134A1
    公开(公告)日:2016-03-10
    Disclosed are heteroaryl derivatives, pharmaceutical composition and uses in the manufacture of a medicine for treating respiratory diseases, especially for chronic obstructive pulmonary disease (COPD).
    公开的是杂芳基衍生物、药物组合物及其在制造用于治疗呼吸道疾病、特别是慢性阻塞性肺病(COPD)的药物中的用途。
  • 芳杂环类衍生物及其在药物中的应用
    申请人:广东东阳光药业有限公司
    公开号:CN105399698B
    公开(公告)日:2018-08-10
    本发明公开了芳杂环类衍生物及其在药物中的应用,具体地,本发明提供一类芳杂环化合物或其立体异构体,几何异构体,互变异构体,消旋体,氮氧化物,合物,溶剂化物,代谢产物,药学上可接受的盐或前药,以及含有本发明化合物的药物组合物。本发明还公开了本发明化合物或其药物组合物在制备药物中的用途,该药物用于治疗呼吸疾病,特别是慢性阻塞性肺疾病(COPD)。
  • [EN] COMPOUNDS<br/>[FR] COMPOSÉS
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2017012576A1
    公开(公告)日:2017-01-26
    Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis(ALS).
    揭示了一种抑制LRRK2激酶活性的新化合物,以及它们的制备方法、含有它们的组合物以及它们在治疗或预防由LRRK2激酶活性特征的疾病中的应用,例如帕森病、阿尔茨海默病和肌萎缩侧索硬化症(ALS)。
  • 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
    申请人:Boehringer Ingelheim International GmbH
    公开号:US20200123140A1
    公开(公告)日:2020-04-23
    Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    公开了化学式A的4-嘧啶-5-基甲基吗啉及其药用盐,其中R1和R2如本文所定义。还公开了它们的制备方法、含有这些化合物的药物组合物,以及它们在治疗中的应用,特别是在与NR2B负变构调节性质相关的疾病的治疗或预防中的应用。
  • 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
    申请人:Boehringer Ingelheim International GmbH
    公开号:US20200121691A1
    公开(公告)日:2020-04-23
    Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    揭示了具有A式的4-吡嗪-2-甲基-吗啉及其药用盐,其中R1和R2如本文所定义。还揭示了它们的制备方法,含有这些化合物的药物组合物,以及它们在治疗中的应用,特别是在与NR2B负向变构调节性质相关的疾病的治疗或预防中。
查看更多